# Indications for Testing among Reported Cases of Hepatitis C Virus Infection from Enhanced Hepatitis Surveillance Sites—United States, 2004 - 2010

Reena Mahajan, Stephen J Liu, Monina Klevens, and Scott D Holmberg Centers for Disease Control and Prevention (CDC)

# BACKGROUND

- Estimated 3.2 million persons with chronic hepatitis C infection (HCV); one-half are unaware of their infection
- 75% born from 1945-1965
- Providers hesitant to elicit risk factor history resulting in under-diagnosis
- CDC has recently released recommendations for a one-time HCV test for persons born from 1945-1965

#### **OBJECTIVE**

 We examined indications for testing by birth cohort (before 1945, 1945-1965, and after 1965) among persons with past or current HCV

# **METHODS**

- Analyzed chronic HCV cases reported from 2004-2010 from 4 hepatitis surveillance sites: Colorado, Connecticut, Minnesota, and New York state
- Positive HCV laboratory markers reported to health departments
- Health departments conducted a medical chart review of the case to abstract demographic and indications for testing
- Information abstracted using standardized case report forms designed by CDC
- Case report forms compiled into a surveillance database and sent to CDC

Figure 1: Sample chronic HCV risk indicators from case report forms

|  | YES | NO | UNK |
|--|-----|----|-----|
| Did the patient receive a blood transfusion prior to 1992?                                       |     |    |     |
| Did the patient receive an organ transplant prior to 1992?                                       |     |    |     |
| Did the patient receive clotting factor concentrates produced prior to 1987?                     |     |    |     |
| Was the patient ever on long-term hemodialysis?  |     |    |     |
| Has the patient ever injected drugs not prescribed by a doctor even if only once or a few times? |     |    |     |
| How many sex partners has the patient had (approximate lifetime)?                                |     |    |     |
| Was the patient ever incarcerated?   |     |    |     |
| Was the patient ever treated for a sexually transmitted disease?                                 |     |    |     |
| Was the patient ever a contact of a person who had hepatitis?                                    |     |    |     |
| If yes, type of contact<br>Sexual  |     |    |     |

#### **RESULTS**

**Table 1:** Characteristics of HCV cases with reported CDC risk indications from four enhanced surveillance sites, 2004-2010

|                                    | Total<br>(N=110,223)<br>% | Age<br>(1945-1965)<br>(N=74,578)<br>% | CDC risk<br>indications*<br>(N=29,544)<br>% |
|------------------------------------|---------------------------|---------------------------------------|---|
| GENDER                             |                           |                                       |   |
| Male                               | 66                        | 69                                    | 65  |
| Female                             | 33                        | 30                                    | 35  |
| RACE                               |                           |                                       |   |
| White                              | 50                        | 50                                    | 63  |
| Black                              | 18                        | 21                                    | 18  |
| Hispanic                           | 15                        | 13                                    | 13  |
| Asian/<br>Pacific Islander         | 2                         | 1                                     | 1   |
| American Indian/<br>Alaskan Native | 1                         | 1                                     | 2   |
| Multiple                           | 1                         | 1                                     | 1   |
| Unknown                            | 13                        | 3                                     | 2   |

# **Table 2.** CDC risk indications among HCV cases from four surveillance sites by birth cohort, 2004-2010


|  | Total**<br>(N=29,544)<br>% | Born before<br>1945<br>(N=2,283)<br>% | Born from<br>1945-1965<br>(N=19,074)<br>% | Born after<br>1965<br>(N=8,172)<br>% |
|--|----------------------------|---------------------------------------|---|--------------------------------------|
| CDC RISK INDICATIONS                             |                            |                                       |   |                                      |
| Injection drug use                               | 62                         | 21                                    | 60  | 80                                   |
| Elevated liver enzyme(s)                         | 39                         | 54                                    | 43  | 26                                   |
| Receipt of blood or blood products prior to 1992 | 13                         | 37                                    | 13  | 5                                    |
| Hemodialysis                                     | 2                          | 7                                     | 2   | 1                                    |
| Transplant history prior to 1992                 | 1                          | 1                                     | <1  | <1                                   |
| Mother-to-child transmission                     | <1                         | 0                                     | 0   | <1                                   |
| Healthcare exposure                              | <1                         | 1                                     | <1  | <1                                   |
| >1 CDC risk indicator                            | 17                         | 20                                    | 18  | 12                                   |

#### Table 1:

- Cases born during 1945-1965 were male (69%) and white (50%)
- Cases with CDC risk indications had similar demographics

\*CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR-19).

\*\* Cases may have more than one risk indication/reason for testing specified so totals may add up to >100%.



## Table 2:

- Of those with any CDC risk indication, overall 62% of cases reported history of injection drug use (IDU)
- Main risk indicators:
  - Born from 1945-1965, 60% IDU
  - Younger (>1965), 80% IDU
  - Older (<1945), 54% elevated liver enzymes</li>

# **DISCUSSION**

- Among cases reported from 4 surveillance sites, 68% were born from 1945-1965, whereas only 27% had one or more CDC risk indications
- Prevalence of CDC risk indications was similar across three birth cohorts (data not shown)
- Injection drug use was the primary risk factor for those born from 1945-1965 and after 1965
- Overall, 74% of reported cases were born from 1945-1965 or had a history of injection drug use
- Data support augmenting HCV risk-based screening with recent CDC recommendations regarding screening of adults in the 1945-1965 birth cohort

## LIMITATIONS

- Analysis based upon known HCV cases, so use for screening must be interpreted cautiously
- Data may not be nationally representative
- Missing reason for testing and risk data may underreport usefulness of risk-based assessment

# **ACKNOWLEDGMENTS**

Colorado Department of Public Health and Environment;

Connecticut Department of Health; Minnesota Department of Health; and New York State Department of Health

# DISCLOSURE STATEMENT

The authors have no financial disclosures or conflicts of interest to report.

Contact information: REENA MAHAJAN

Email address: vif5@cdc.gov

